trending Market Intelligence /marketintelligence/en/news-insights/trending/yusgyxrtupv0i4gfak8vfg2 content esgSubNav
In This List

Dova Pharmaceuticals prices common stock offering

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Dova Pharmaceuticals prices common stock offering

Dova Pharmaceuticals Inc. priced its underwritten public offering of 2.5 million common shares at $32 each.

The Durham, N.C.-based company expects to raise gross proceeds of about $80 million through the offering, which is expected to close Feb. 27, subject to customary closing conditions.

Dova Pharmaceuticals, which develops drugs for platelet deficiency, granted underwriters a 30-day option to buy up to an additional 375,000 at the offering price.

J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group LLC are acting as joint book-running managers for the offering.